Your browser is no longer supported. Please, upgrade your browser.
TPST [NASD]
Tempest Therapeutics, Inc.
Index- P/E- EPS (ttm)-21.16 Insider Own1.10% Shs Outstand6.72M Perf Week-7.60%
Market Cap60.41M Forward P/E- EPS next Y-5.35 Insider Trans0.00% Shs Float6.05M Perf Month-28.97%
Income-27.90M PEG- EPS next Q-1.77 Inst Own32.00% Short Float0.76% Perf Quarter-39.78%
Sales- P/S- EPS this Y40.60% Inst Trans20.17% Short Ratio1.95 Perf Half Y-58.00%
Book/sh6.48 P/B1.33 EPS next Y35.50% ROA-51.20% Target Price37.00 Perf Year-70.65%
Cash/sh- P/C- EPS next 5Y- ROE-74.50% 52W Range8.00 - 41.55 Perf YTD-73.12%
Dividend- P/FCF- EPS past 5Y45.60% ROI- 52W High-79.23% Beta0.45
Dividend %- Quick Ratio10.10 Sales past 5Y- Gross Margin- 52W Low7.88% ATR0.64
Employees12 Current Ratio10.10 Sales Q/Q- Oper. Margin- RSI (14)30.05 Volatility7.88% 6.25%
OptionableYes Debt/Eq0.00 EPS Q/Q76.00% Profit Margin- Rel Volume0.13 Prev Close8.53
ShortableYes LT Debt/Eq0.34 Earnings- Payout- Avg Volume23.74K Price8.63
Recom2.00 SMA20-14.85% SMA50-29.19% SMA200-49.30% Volume3,173 Change1.17%
Nov-18-21 08:00AM  
Nov-12-21 07:00AM  
Nov-10-21 04:05PM  
Nov-09-21 08:00AM  
Nov-08-21 08:00AM  
Oct-01-21 08:00AM  
Sep-20-21 08:00AM  
Sep-13-21 08:00AM  
Sep-09-21 04:01PM  
Aug-12-21 04:01PM  
Aug-09-21 08:00AM  
Jul-09-21 08:00AM  
Jul-01-21 04:00PM  
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha, and is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company is headquartered in South San Francisco, California.